Botanix Webinar – Monday 20 October:

Registration Information Philadelphia PA and Phoenix AZ 16 October 2025:

Commercial dermatology company, Botanix Pharmaceuticals Limited (ABN 70 009 109 755) (ASX:BOT, “Botanix” or “the Company”), announces that it will host a webinar to provide a comprehensive update on the Company’s Quarterly Activity Report and 4C Quarterly Cash Flow Report.

Executive Chairman Vince Ippolito, Chief Executive Officer Dr Howie McKibbon and US Chief Financial Officer Chris Lesovitz will include an update on the launch momentum for Sofdra® (sofpironium) topical gel, 12.45%.

The webinar will be held on Monday, 20 October 2025, at 11.00 am AEDT (Sydney/Melbourne)/8.00 am AWST (Perth).

Interested participants must register before the webinar using the link below. Dialin details will be sent in return.

Date: 20 October 2025 Time: 11.00 am AEDT (Sydney/Melbourne), 8.00 am AWST (Perth) To register: https://us06web.zoom.us/webinar/register/WN_-oGtp6viSHG5NwrKmitAsw Dial in details: Will be sent to you directly upon registration

BOT enters a trading halt based on

"pending release of an announcement regarding US Food and Drug Administration (FDA) communication in respect of the Botanix New Drug Application"

I've been through a few of these over the years and this doesn't sound positive. I'm expecting this announcement to disappoint.

I sold out a week or two back so I'm hoping I'm the one that'll be disappointed and not those who have a position....best of luck.